GMAB – Genmab A/S
Genmab A/SGMAB
$20.50Name : Genmab A/S
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $12,643,662,848.00
EPSttm : 1.7
Genmab A/S
$20.50
1.11%$0.23Float Short %
0.36
Margin Of Safety %
47
Put/Call OI Ratio
0.49
EPS Next Q Diff
0.12
EPS Last/This Y
-0.36
EPS This/Next Y
0.3
Price
20.5
Target Price
30.97
Analyst Recom
1.7
Performance Q
1.79
Relative Volume
0.47
Beta
0.95
Ticker: GMAB
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | GMAB | 21.77 | 1.16 | 0.19 | 3073 |
| 2025-06-03 | GMAB | 21.35 | 1.02 | 7.33 | 3335 |
| 2025-06-04 | GMAB | 21.78 | 1.03 | 1.76 | 3361 |
| 2025-06-05 | GMAB | 21.8 | 1.03 | 1.36 | 3395 |
| 2025-06-06 | GMAB | 22.2 | 1.02 | 0.65 | 3418 |
| 2025-06-09 | GMAB | 22.25 | 1.02 | 0.29 | 3445 |
| 2025-06-10 | GMAB | 22.82 | 1.02 | 0.03 | 3442 |
| 2025-06-11 | GMAB | 22.62 | 1.00 | 2.54 | 3477 |
| 2025-06-12 | GMAB | 23.09 | 1.03 | 1.00 | 3551 |
| 2025-06-13 | GMAB | 22.82 | 1.03 | 0.00 | 3557 |
| 2025-06-16 | GMAB | 22.87 | 0.92 | 0.00 | 3773 |
| 2025-06-17 | GMAB | 22.03 | 0.91 | 21.25 | 3795 |
| 2025-06-18 | GMAB | 21.56 | 1.03 | 0.00 | 4065 |
| 2025-06-20 | GMAB | 21.16 | 1.02 | 0.24 | 4086 |
| 2025-06-23 | GMAB | 20.66 | 0.48 | 2.15 | 2925 |
| 2025-06-24 | GMAB | 20.75 | 0.49 | 0.09 | 2958 |
| 2025-06-25 | GMAB | 20.53 | 0.49 | 1.33 | 2973 |
| 2025-06-26 | GMAB | 20.73 | 0.49 | 0.00 | 2978 |
| 2025-06-27 | GMAB | 20.5 | 0.49 | 0.33 | 2979 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | GMAB | 21.77 | 5.9 | 80.0 | 1.34 |
| 2025-06-03 | GMAB | 21.35 | 5.9 | 45.6 | 1.34 |
| 2025-06-04 | GMAB | 21.77 | 5.9 | 64.6 | 1.34 |
| 2025-06-05 | GMAB | 21.81 | 5.9 | 26.8 | 1.34 |
| 2025-06-06 | GMAB | 22.20 | 5.9 | 56.0 | 1.34 |
| 2025-06-09 | GMAB | 22.25 | 5.9 | 50.3 | 1.34 |
| 2025-06-10 | GMAB | 22.83 | 5.9 | 97.0 | 1.34 |
| 2025-06-11 | GMAB | 22.69 | 5.9 | 27.0 | 1.34 |
| 2025-06-12 | GMAB | 23.09 | 5.9 | 64.1 | 1.34 |
| 2025-06-13 | GMAB | 22.81 | 5.9 | 41.3 | 1.34 |
| 2025-06-16 | GMAB | 22.87 | 5.9 | 46.3 | 1.34 |
| 2025-06-17 | GMAB | 22.02 | 5.9 | -8.1 | 1.34 |
| 2025-06-18 | GMAB | 21.56 | 5.9 | -27.0 | 1.34 |
| 2025-06-20 | GMAB | 21.16 | 5.9 | 32.2 | 1.34 |
| 2025-06-23 | GMAB | 20.67 | 5.9 | 39.7 | 1.34 |
| 2025-06-24 | GMAB | 20.74 | 5.9 | 77.2 | 1.34 |
| 2025-06-25 | GMAB | 20.53 | 5.9 | 33.8 | 1.34 |
| 2025-06-26 | GMAB | 20.72 | 5.9 | 74.9 | 1.34 |
| 2025-06-27 | GMAB | 20.50 | 5.9 | 44.3 | 1.34 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | GMAB | 0 | -0.10 | 0.45 |
| 2025-06-03 | GMAB | 0 | -0.10 | 0.45 |
| 2025-06-04 | GMAB | 0 | -0.10 | 0.45 |
| 2025-06-05 | GMAB | 0 | -0.10 | 0.45 |
| 2025-06-06 | GMAB | 0 | -0.10 | 0.45 |
| 2025-06-09 | GMAB | 0 | -0.10 | 0.45 |
| 2025-06-10 | GMAB | 0 | -0.10 | 0.45 |
| 2025-06-11 | GMAB | 0 | -0.10 | 0.39 |
| 2025-06-12 | GMAB | 0 | -0.10 | 0.39 |
| 2025-06-13 | GMAB | 0 | -0.10 | 0.39 |
| 2025-06-16 | GMAB | 0 | -0.16 | 0.39 |
| 2025-06-17 | GMAB | 0 | -0.16 | 0.39 |
| 2025-06-18 | GMAB | 0 | -0.16 | 0.39 |
| 2025-06-20 | GMAB | 0 | -0.16 | 0.39 |
| 2025-06-23 | GMAB | 0 | -0.13 | 0 |
| 2025-06-24 | GMAB | 0 | -0.13 | 0.39 |
| 2025-06-25 | GMAB | 0 | -0.13 | 0.39 |
| 2025-06-26 | GMAB | 0 | -0.13 | 0.36 |
| 2025-06-27 | GMAB | 0 | -0.13 | 0.36 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.31
Avg. EPS Est. Current Quarter
0.34
Avg. EPS Est. Next Quarter
0.43
Insider Transactions
Institutional Transactions
-0.13
Beta
0.95
Average Sales Estimate Current Quarter
5927
Average Sales Estimate Next Quarter
6262
Fair Value
30.14
Quality Score
100
Growth Score
100
Sentiment Score
44
Actual DrawDown %
58.2
Max Drawdown 5-Year %
-63.1
Target Price
30.97
P/E
11.63
Forward P/E
11.48
PEG
1.27
P/S
3.9
P/B
2.46
P/Free Cash Flow
10.82
EPS
1.76
Average EPS Est. Cur. Y
1.34
EPS Next Y. (Est.)
1.64
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
35.11
Relative Volume
0.47
Return on Equity vs Sector %
-3.2
Return on Equity vs Industry %
14.7
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.04
EBIT Estimation
44.3
Genmab A/SSector: Healthcare
Industry: Biotechnology
Employees: 2638
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
stock quote shares GMAB – Genmab A/S Stock Price stock today
news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch GMAB – Genmab A/S yahoo finance google finance
stock history GMAB – Genmab A/S invest stock market
stock prices GMAB premarket after hours
ticker GMAB fair value insiders trading